Daily4h
Gilead Sciences sets aside USD 200 million to resolve HIV drug investigation
Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...
Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
Lawyer Monthly7h
Gilead Sciences Sets Aside $200M for HIV Drug Settlement
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.
bhekisisa.org7h
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...